SCHEMBL4124511

SCHEMBL4124511

CC(C)(C)OC(=O)C(N)CCC1=CC(=O)c2ccccc2C1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
NSD2 O96028 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MALT1 Q9UDY8 1/20 0.41
CYP19A1 P11511 1/20 0.41
LTA4H P09960 1/20 0.40
PKM P14618 2/20 0.38
CDC25A P30304 3/20 0.36
CDC25B P30305 3/20 0.36
PTPRC P08575 2/20 0.36
IDO1 P14902 2/20 0.36
ALDH1A1 P00352 2/20 0.36
LMNA P02545 2/20 0.36
GAA P10253 2/20 0.36
MAPT P10636 2/20 0.36
HPGD P15428 2/20 0.36
MAPK1 P28482 2/20 0.36
ATM Q13315 2/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4105354 0.87 MEN1 (0.43) MEN1KMT2ANSD2L3MBTL1MALT1
SCHEMBL4105352 0.76 MALT1 (0.62) MEN1KMT2ANSD2L3MBTL1MALT1
SCHEMBL27878054 0.76 LTA4H (0.55) MEN1KMT2ALTA4HHPGDHTT
SCHEMBL2307679 0.76 LTA4H (0.55) MEN1KMT2ALTA4HHPGDHTT
SCHEMBL2307682 0.76 LTA4H (0.55) MEN1KMT2ALTA4HHPGDHTT
SCHEMBL4034341 0.74 PTPRC (0.41) MEN1KMT2ANSD2L3MBTL1MALT1
Hydrochloric Acid SCHEMBL29264506 0.74 LTA4H (0.54) MEN1KMT2ALTA4HIDO1HPGD
SCHEMBL4124507 0.74 MALT1 (0.60) MEN1KMT2AMALT1CYP19A1IDO1
SCHEMBL4116683 0.74 P4HB (0.42) MEN1KMT2ACDC25ACDC25BALDH1A1
SCHEMBL4116064 0.74 MAPT (0.45) MEN1KMT2AMALT1CDC25ACDC25B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247472-A1 TYPE 1, 4-NAPHTOQUINONE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USE OF THESE COMPOUNDS AS ANTI-CANCER AGENTS FLUOFARMA (FR) 2009-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247472-A1 TYPE 1, 4-NAPHTOQUINONE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USE OF THESE COMPOUNDS AS ANTI-CANCER AGENTS CCNA1, MKI67, CCNT1 MEN1 937/4885KMT2A 3068/4885NSD2 2402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.